What Bioavailability Really Means on a Supplement Label

▶ Watch the video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Bioavailability describes the rate and extent to which an active ingredient becomes available in systemic circulation. Absolute bioavailability compares dose-normalized exposure with an intravenous reference dose; relative bioavailability compares two non-intravenous formulations or conditions of administration. A supplement advertised as "more bioavailable" may be referring to either comparison, or may not identify the comparator at all. Three measurements make bioavailability usable: AUC, total exposure; Cmax, peak concentration; and Tmax, time to peak. A small 2008 pilot study found one curcumin formulation produced an AUC 6.93 times that of standard curcumin powder — a relative, not absolute, comparison. MIHIYO Labs formulates its oral dissolving strip (ODS) products around that distinction.

What Does "Bioavailability" Actually Mean?

Bioavailability describes the rate and extent to which an active ingredient becomes available in systemic circulation.¹ In practice, AUC is commonly used to characterize total exposure, while Cmax and Tmax help characterize the rate at which that exposure develops.¹ It is not the same question as "how much did I swallow." A capsule can contain an accurately measured, generously dosed active ingredient and still deliver only a small fraction of it to the bloodstream, because absorption, gut-wall processing, and liver metabolism all happen between the label and the blood draw.

I hold every MIHIYO formulation to two design questions built on that definition: how much of a given dose reaches circulation, and how quickly it gets there. The two are part of the same formal definition, but they don't move together in practice — a product can have high total exposure and a slow climb to it, or a fast climb to a total exposure that never gets very high. When "bioavailable" is used as a single all-purpose adjective rather than tied to one of these specific measurements, that difference gets erased. A label that uses the word without identifying the reference product or the pharmacokinetic measurement behind it does not give the reader enough information to evaluate what was actually demonstrated.

Absolute vs. Relative Bioavailability: The Distinction Labels Don't Have to Explain

There are two different ways to measure bioavailability, and they answer two different questions. Absolute bioavailability compares dose-normalized systemic exposure after an oral or other extravascular dose with exposure after an intravenous reference dose — intravenous administration is the reference point because it enters the bloodstream directly, without passing through the gut wall or liver first.² Relative bioavailability instead compares systemic exposure between two non-intravenous formulations, or between the same formulation under two different conditions of administration (fed versus fasted, for example), without using an intravenous reference at all.² Regulators use both: absolute bioavailability data anchors how much of a drug's exposure the body actually sees. When a relative bioavailability comparison is used to establish average bioequivalence for a generic drug, FDA generally recommends evaluating whether the 90 percent confidence intervals for the geometric mean ratios of AUC and Cmax fall within 80.00 to 125.00 percent for an unscaled average-bioequivalence analysis; different approaches can apply to highly variable drugs, narrow therapeutic index drugs, and certain other product types.¹⁰ That recommendation is specific to generic-drug approval, not a standard every relative bioavailability comparison is held to.

Dietary supplements are ordinarily marketed in non-intravenous forms, so a consumer-facing "more bioavailable" claim may describe a relative comparison between formulations rather than an absolute one. Absolute bioavailability is not unmeasurable for a supplement ingredient, though — researchers can measure it experimentally when a suitable intravenous reference or another scientifically valid approach is available² — it just means a shopper reading a label has no way to know, from the claim alone, which comparison is actually behind it. A small 2008 pilot crossover study of a proprietary curcumin preparation, BCM-95, enrolled 11 healthy subjects and reported an AUC for BCM-95 about 6.93 times that of standard curcumin powder — a relative bioavailability result.³ The study did not include an intravenous curcumin arm, so it could not and did not establish absolute bioavailability, and several of its authors were affiliated with the company that manufactures BCM-95, which is worth knowing when weighing the result.³ A 2024 methodological study of 171 curcumin systematic reviews found that the kind of subgroup or sensitivity analysis needed to account for differences in bioavailability between curcumin formulations was specified in the methods of only 3.5 percent of reviews and reported in the results of only 6.4 percent, and concluded that pooled results across such reviews should be read with caution as a result.⁴ The 6.93-fold figure itself was not fabricated. Knowing it is a small, company-affiliated, oral-to-oral comparison — not an absolute measurement — is the context a buyer actually needs.

What Does AUC Measure?

AUC, or area under the curve, plots a drug's blood concentration against time after dosing and calculates the total area under that curve — a single number representing total systemic exposure, not a peak or a speed.¹ Two products can produce very different concentration curves and still land on the same AUC, because AUC only captures the total, not the shape.

AUC is also sensitive to conditions that ordinary use doesn't standardize the way a clinical trial does — meal timing chief among them. The current U.S. prescribing information for nilotinib (Tasigna), a chronic myeloid leukemia drug, reports that systemic exposure, measured by AUC, increased by 82 percent when a dose was given 30 minutes after a high-fat meal — a large enough shift that the label requires the drug be taken on an empty stomach.⁵ That is itself an example of a relative bioavailability comparison — the same formulation under two conditions of administration, not two different products. That is also one reason "take with food" or "take on an empty stomach" instructions matter: they can function as bioavailability and safety controls, though some food instructions are also intended to improve gastrointestinal tolerability rather than absorption specifically.

What Is Cmax?

Cmax is the highest concentration a dose actually reaches in the blood, and it depends on more than dose size alone — route and absorption saturation matter too.¹ In a classic pharmacokinetic study, the same 1.25-gram dose of vitamin C produced a measured mean peak of about 135 micromoles per liter given orally, compared with about 885 micromoles per liter given intravenously — the same dose, roughly a 6.6-fold difference in peak concentration from route alone.⁶ Pharmacokinetic modeling in the same study went further: a maximum-tolerated oral regimen (3 grams every 4 hours) was predicted to reach only about 220 micromoles per liter, while a 50-gram intravenous dose was predicted to reach roughly 13,400 micromoles per liter.⁶ Oral absorption of vitamin C saturates well before the gut can move a large dose into the blood, so beyond a certain point, a larger labeled dose of a poorly absorbed ingredient does not necessarily produce a proportionally higher blood concentration.

What Is Tmax?

Tmax is simply the time it takes to reach that peak concentration.¹ Dosage form and route can influence Tmax, but a shorter disintegration or dissolution time does not by itself establish a shorter Tmax — that has to be measured in a pharmacokinetic study, not assumed from how fast a product dissolves. I cover Tmax in more depth, with real numbers across several supplement actives, in a dedicated article on supplement onset time — it is worth treating as its own topic rather than a footnote here.

Absolute and Relative Bioavailability, Side by Side

A number under the relative-bioavailability column, like the BCM-95 curcumin example above, can sound dramatic without the reference product being clearly identified. Neither measurement is the "wrong" one on its own — the mistake is reading a relative number as if it answered the absolute question. "6.93 times more bioavailable" means the formulation outperformed one specific comparison product in one small study; it does not mean the formulation delivers most of the administered dose.

What This Means for MIHIYO's Formulation Choices

I do not build a MIHIYO Labs formulation around a bioavailability adjective. I build it around which of the two pharmacokinetic questions — how much, or how fast — actually matters for that ingredient, because the honest answer is different for each active in the product line.

Caffeine is the clearest example, and it is the active in the Energy-Focus ODS. Swallowed caffeine already reaches near-complete oral bioavailability, since it is absorbed rapidly from the gastrointestinal tract with minimal loss before reaching systemic circulation.⁷ That means an absolute-bioavailability pitch for a caffeine strip would be formulating a solution to a problem that mostly does not exist for this molecule — there is very little unabsorbed dose left to rescue. Dosage form and route can influence Tmax, but a shorter oral disintegration time does not establish a shorter Tmax on its own. Whether the Energy-Focus strip produces a different time-to-peak than a swallowed caffeine product is currently unknown, because the finished product has not undergone a human pharmacokinetic comparison. I describe rapid oral disintegration as a formulation target, not as evidence of faster absorption or onset. I write more about how first-pass metabolism explains why caffeine and other actives land so differently on this question in a separate article on the first-pass effect, and about why dosage form is a design variable in its own right, not an afterthought to the ingredient list, in the dosage form decision.

None of this is a bioavailability claim about a MIHIYO product specifically. The cited studies were run on the molecules — caffeine, curcumin, vitamin C — in research settings, not on MIHIYO's own strips, and I have not run a human pharmacokinetic study on any current formulation. What the pharmacology does is discipline the design decision: it tells me which lever, dose size or dissolution speed, is actually worth pulling for a given active, instead of defaulting to a generic "better absorption" story for every ingredient regardless of its own chemistry.

Where Bioavailability Numbers Fall Short as a Buying Signal

A bioavailability number, even a real one, has real limits as a way to judge a supplement.

Dietary supplement manufacturers are not generally required to demonstrate bioequivalence to a reference product under the generic-drug framework, and the FDA does not require premarket approval of dietary supplement products the way it does new drugs.⁹¹⁰ That gap is a gap in required study design, not a license to say anything: the FTC still requires that any bioavailability claim, and the overall impression it creates, be truthful, not misleading, and backed by adequate substantiation for the specific product being marketed — an ingredient-level study does not automatically substantiate a finished-product claim.⁸

A bioavailability figure also says nothing on its own about clinical effect. Higher exposure to an ingredient is not automatically a larger benefit; it depends entirely on the pharmacology of that specific compound, its dose-response relationship, and what it is actually being used for. And these numbers vary by individual — the vitamin C data above reflect averages from controlled studies, not a fixed outcome for any one person's gut, transporters, or metabolism. A bioavailability claim answers a narrow, specific pharmacokinetic question. It does not, by itself, answer whether a product works.

The Bottom Line

Bioavailability describes the rate and extent to which an active ingredient becomes available in systemic circulation, and asking "relative to what" is the single most useful question a supplement buyer can bring to that word. Absolute bioavailability compares dose-normalized exposure to an intravenous reference dose; relative bioavailability compares two non-intravenous formulations, or the same formulation under different conditions, against each other. In supplement marketing, "more bioavailable" may refer to a relative comparison, but the only way to know is to identify the reference product and pharmacokinetic measurement actually used. AUC, Cmax, and Tmax are the three measurements underneath both — total exposure, peak concentration, and time to peak — and each answers a different practical question about a dose. At MIHIYO Labs, I use those three measurements to decide what a given active actually needs from its dosage form, rather than reaching for "bioavailable" as a stand-in for a number I have not measured.

References

1. Price G, Patel DA. Drug Bioavailability. StatPearls Publishing. Updated July 30, 2023. NCBI Bookshelf: NBK557852. https://www.ncbi.nlm.nih.gov/books/NBK557852/
2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Bioavailability Studies Submitted in NDAs or INDs — General Considerations. Guidance for Industry, final. April 2022. https://www.fda.gov/media/121311/download
3. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95®CG (Biocurcumax™), A Novel Bioenhanced Preparation of Curcumin. Indian Journal of Pharmaceutical Sciences. 2008;70(4):445-449. PMC2792534. https://pmc.ncbi.nlm.nih.gov/articles/PMC2792534/
4. Bučević Popović V, Karahmet Farhat E, Banjari I, Jeličić Kadić A, Puljak L. Bioavailability of Oral Curcumin in Systematic Reviews: A Methodological Study. Pharmaceuticals (Basel). 2024;17(2):164. DOI: 10.3390/ph17020164. https://pmc.ncbi.nlm.nih.gov/articles/PMC10891944/
5. Novartis Pharmaceuticals Corporation. TASIGNA (nilotinib) capsules — Prescribing Information. FDA-approved labeling, via DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6093952a-5248-45cb-ad17-33716a411146
6. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Annals of Internal Medicine. 2004;140(7):533-537. PMID: 15068981. DOI: 10.7326/0003-4819-140-7-200404060-00010. https://pubmed.ncbi.nlm.nih.gov/15068981/
7. Evans J, Richards JR, Battisti AS. Caffeine. StatPearls Publishing. Updated May 29, 2024. NCBI Bookshelf: NBK519490. https://www.ncbi.nlm.nih.gov/books/NBK519490/
8. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
9. National Institutes of Health, Office of Dietary Supplements. Dietary Supplements: What You Need to Know. Updated January 4, 2023. https://ods.od.nih.gov/factsheets/WYNTK-Consumer/
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application. Guidance for Industry, final. May 2026. https://www.fda.gov/media/192774/download

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.